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Abstract
Human steroid biosynthesis depends on a specifically regulated cascade of enzymes including 3b-hydroxysteroid
dehydrogenases (HSD3Bs). Type 2 HSD3B catalyzes the conversion of pregnenolone, 17a-hydroxypregnenolone and
dehydroepiandrosterone to progesterone, 17a-hydroxyprogesterone and androstenedione in the human adrenal cortex
and the gonads but the exact regulation of this enzyme is unknown. Therefore, specific downregulation of HSD3B2 at
adrenarche around age 6–8 years and characteristic upregulation of HSD3B2 in the ovaries of women suffering from the
polycystic ovary syndrome remain unexplained prompting us to study the regulation of HSD3B2 in adrenal NCI-H295R cells.
Our studies confirm that the HSD3B2 promoter is regulated by transcription factors GATA, Nur77 and SF1/LRH1 in concert
and that the NBRE/Nur77 site is crucial for hormonal stimulation with cAMP. In fact, these three transcription factors
together were able to transactivate the HSD3B2 promoter in placental JEG3 cells which normally do not express HSD3B2. By
contrast, epigenetic mechanisms such as methylation and acetylation seem not involved in controlling HSD3B2 expression.
Cyclic AMP was found to exert differential effects on HSD3B2 when comparing short (acute) versus long-term (chronic)
stimulation. Short cAMP stimulation inhibited HSD3B2 activity directly possibly due to regulation at co-factor or substrate
level or posttranslational modification of the protein. Long cAMP stimulation attenuated HSD3B2 inhibition and increased
HSD3B2 expression through transcriptional regulation. Although PKA and MAPK pathways are obvious candidates for
possibly transmitting the cAMP signal to HSD3B2, our studies using PKA and MEK1/2 inhibitors revealed no such
downstream signaling of cAMP. However, both signaling pathways were clearly regulating HSD3B2 expression.
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Introduction
Steroid hormone production depends on cholesterol and a well
described cascade of steroid enzymes that are specifically regulated
(e.g. developmentally and tissue specific) to fulfill diverse biological
functions [1,2]. The group of 3b-hydroxysteroid dehydrogenase
(HSD3B) enzymes plays a central role early in this cascade for the
biosynthesis of mineralocorticoids, glucocorticoids and sex steroids
[2]. HSD3Bs are membrane bound enzymes which catalyze two
reactions, the conversion of the hydroxyl group to a keto group on
carbon 3, and the isomerization of the double bond from the B
ring (D5 steroid) to the A ring (D4 steroid) [1]. These reactions
depend on the co-factor nicotinamide adenine dinucleotide (NAD)
[3]. The human HSD3B family consists of two members, namely
the HSD3B type I (HSD3B1) and the HSD3B type II (HSD3B2).
HSD3B1 is mainly expressed in the placenta, the mammary
glands, the prostate as well as in peripheral tissues such as the skin
and the adipose tissue [4,5]. The HSD3B1 gene on chromosome
1p13.1 encodes a protein of 372 amino acids [2]. By contrast,
HSD3B2 is mainly expressed in the adrenals and the gonads
[6,7,8]. It is also located on chromosome 1p13.1 and encodes a
protein of 371 amino acids which is 93.5% identical with the type I
enzyme. In the human adrenal cortex HSD3B2 acts as a D5–D4-
isomerase because it converts D5 steroids (pregnenolone, 17a-
hydroxypregnenolone, dehydroepiandrosterone (DHEA)) to D4
steroids (progesterone, 17a-hydroxyprogesterone, androstenedi-
one (D4A)).
The human fetal adrenal does not really express HSD3Bs and
predominantly produces DHEA [1]; an exception occurs around
6–12 weeks gestation when timely restricted HSD3B2 expression
leads to cortisol synthesis and an inhibition of DHEA production
[9]. This specific window of HSD3B2 expression is responsible for
safeguarding the female external genitalia from virilization during
fetal development [9]. After birth, the definitive adrenal cortex
consists of the zona glomerulosa and the zona fasciculata which
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both abundantly express HSD3B2 for mineralocorticoid and
glucocorticoid production throughout life. By contrast, the third
and innermost layer of the adrenal cortex, the zona reticularis,
slowly develops after birth and becomes functionally active for
androgen production around 6–8 years of age during an event
called adrenarche [10,11]. Although the biology of adrenarche is
not fully understood, a major characteristic of steroidogenesis at
adrenarche is a specific downregulation of HSD3B2 expression in
the zona reticularis [12,13]. Furthermore, specific overexpression
of HSD3B2 has been found in the ovaries of women with
polycystic ovary syndrome (PCOS) [14,15], which is the most
common endocrine disorder associated with hyperandrogenism
and infertility in females [16]. By contrast, deficiency of HSD3B2
through genetic mutations causes congenital adrenal hyperplasia
which manifests as primary adrenal insufficiency and disordered
sexual development in both sexes causing moderate to severe
undervirilization of 46,XY and mild virilization of 46,XX infants
[17,18,19].
Thus, HSD3B2 and its specific regulation seem to play an
important role in biology. However, so far little is known about the
exact regulation of HSD3B2. Previous studies have shown that
transcription of the HSD3B2 gene is activated by the transcription
factor steroidogenic factor 1 (SF1) through stimulation of phorbol
esters [20]. It is known that the human HSD3B2 promoter
contains four consensus GATA elements which can be activated
by GATA-4 and GATA-6 and act in concert with the nuclear
receptors SF1 and liver receptor homolog 1 (LRH1) [21]. Also the
transcription factor Nur77, also known as nerve growth factor IB
(NGFI-B), regulates HSD3B2 transcription in granulosa as well as
Leydig and adrenal cells [22,23]. Nur77 apparently activates the
HSD3B2 promoter through a nuclear binding response element
(NBRE) site [22,23,24]. Previous studies have also demonstrated
that prolactin stimulated Stat5 activates the human HSD3B2
promoter [25]. Overall, HSD3B2 seems to be clearly regulated at
the transcriptional level while other regulatory mechanisms
remain to be elucidated. Therefore, the aim of our study was to
further investigate the molecular regulation of human HSD3B2 in
the context of adrenal steroidogenesis. For our studies, we used the
human adrenocortical carcinoma NCI-H295R cell line as our cell
model expressing HSD3B2 [26] and the human placental JEG3
cell line as the cell model expressing HSD3B1, but not HSD3B2
[27]. We studied HSD3B2 transcription, expression and function
in NCI-R cells grown under varying culture conditions and under
8Br-cAMP stimulation. Furthermore, signaling studies were
performed testing for involvement of cAMP dependent protein
kinase (PKA) and mitogen activated protein kinase (MAPK)/
extracellular signal-regulated kinases (ERK) in HSD3B2 modula-
tion.
Materials and Methods
Materials
To obtain the HSD3B2 promoter luciferase reporter constructs,
the human HSD3B2 promoter DNA sequences 2101, 2170,
2301 and21050 to +53 were PCR amplified from genomic DNA
extracted from human adrenal NCI-H295R cells using specific
primers (Table 1). Obtained PCR products were cloned into the
mammalian expression vector pGL3 basic (Promega, Madison,
WI, USA) and the new vectors were confirmed by direct
sequencing. Plasmids containing the cDNAs for GATA4/6 and
SF1 were available from other projects [27]. Nur77 was cloned
from total RNA of NCI-R cells via reverse transcription and
specific PCR; the obtained cDNA was then cloned into pcDNA3
(Invitrogen, Life Technologies, Paisley, UK). Mutant constructs
were generated by PCR-based site-directed mutagenesis using the
manufacturer’s protocol (Stratagene AG, Basel, Switzerland) and
the obtained constructs were checked for correct mutations by
direct sequencing. Eight-bromoadenosine 39,59-cyclic monophos-
phate (8Br-cAMP), PD98059 mitogen-activated kinase kinase
(MEK) inhibitor, U0126 MEK inhibitor and H89 cAMP
dependent protein kinase (PKA) inhibitor were purchased from
Sigma-Aldrich (Buchs, Switzerland) and dissolved in DMSO. For
epigenetic experiments, 5-aza-29-deoxycytidine (5-aza-dC) and
trichostatin A (TSA) were purchased from Sigma-Aldrich and
dissolved in DMSO. The chicken peptide antibody against human
HSD3B2 was custom made by Genetel Pharmaceutical Co Ltd
(Guangdong, China). b-actin antibody was received from Sigma-
Aldrich. Secondary goat anti-mouse IgG or goat anti-chicken IgG,
both conjugated with horseradish peroxidase were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Radioactive-
labeled [1,2,6,7(N)-3H] DHEA (63 Ci/mmol) was procured from
PerkinElmer (Boston MA, USA).
Cell Cultures, Transfection and Dual Luciferase Assays
Human adrenocortical NCI-H295R cells were purchased from
American Type Culture Collection (ATCC; CRL-2128). NCI-R
cells were cultured in DMEM/Ham’s F-12 medium containing L-
glutamine and 15 mM HEPES medium (GIBCO, Paisley, UK)
supplemented with 5% NU-I serum (Becton Dickinson, Franklin
Lakes, NJ, USA), 0.1% insulin, transferrin, and selenium (100 U/
ml; GIBCO), penicillin (100 U/ml; GIBCO) and streptomycin
(100 mg/ml; GIBCO). The serum free starvation medium
consisted of DMEM/Ham’s F-12 medium, penicillin (100 U/ml;
GIBCO) and streptomycin (100 mg/ml; GIBCO). Human embry-
onic kidney 293 (HEK293) cells [28] were maintained in DMEM
+4.5 g/L D-glucose with 10% fetal calf serum, penicillin (100 U/
ml; GIBCO), streptomycin (100 mg/ml; GIBCO) and 1% sodium
pyruvate (100mM; GIBCO). NCI-R and HEK293 cells were
transfected with the empty vector pGL3 or specific HSD3B2
promoter-reporter constructs and different transcription factors as
indicated. Transient transfection was carried out in 12-well plates
for 6 hours (Falcon 3043; Becton Dickinson) using Lipofectamine
2000 reagent according to the manufacturer’s instructions
(Invitrogen). Per 12-well, the transfection mixture contained
2.5 mg plasmid DNA and 100 ng Renilla luciferase reporter
(pRL-TK) (Promega, Du¨bendorf, Switzerland) for endogenous
control. Human placental JEG3 cells were purchased from ATCC
(HTB-36TM) and cultured in minimal essential medium (MEM)
with Earle’s salts (GIBCO), 10% fetal bovine serum, 1% L-
glutamine (200mM; GIBCO), penicillin (100 U/ml; GIBCO) and
streptomycin (100 mg/ml; GIBCO). Before transfection, JEG3
cells were divided onto 12-well plates at approximately 50%
confluency. For transfection, cells were then incubated for 6 h with
calcium phosphate precipitates containing the 21050 bp
HSD3B2 promoter reporter plasmid DNA and DNA of expression
vectors for GATA4/6, SF1 and Nur77 (2.5 mg total DNA/
duplicate). Forty-eight hours after transfection, cells were washed
with phosphate buffered saline (PBS) and then assayed for
luciferase activity using the Dual Luciferase Reporter Assay
system and protocol by Promega.
Western Blot Analysis
For protein analyses, treated cells were washed with ice-cold
PBS and harvested in lysis buffer (200 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1 mM EDTA, 1% Triton X-100 and protease
and/or phosphatase inhibitors. Lysates were homogenized by a
25G syringe, centrifuged at 13,0006g for 10 min at 4uC and
supernatants were collected. Protein concentrations of samples
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were measured by the DC Protein Assay (Bio-Rad, Hercules, CA,
USA). For Western blots, 30 mg protein of total cell lysates was
mixed with SDS loading buffer (62.5 mM Tris–HCl, pH 6.8; 2%
sodium dodecylsulfate, 10% glycerol, 100 mM dithiotreitol, 0.01%
bromophenol blue), heated for 5 min at 95uC, separated on a 10%
SDS-PAGE gel and blotted on an Immobilon-P PVDF transfer
membrane (Millipore, Bedford, MA, USA) using the semi-dry
transfer method. Blocking and staining with antibodies was
performed according to manufacturer’s recommendations (Santa
Cruz Biotechnology or Sigma-Aldrich). For HSD3B2 Western,
membranes were blocked with 10% milk, HSD3B2 antibody was
used at 1:109000 and the secondary antibody was dissolved
1:109000 in Tween 20 tris-buffered saline (TTBS) with 5% milk.
Protein bands were visualized by Plus-ECL substrate reagent
(PerkinElmer) and exposed on HyperfilmMP (GE Healthcare
Limited, Buckinghamshire, UK). When tested with different
antibodies, membranes were stripped with 0.2 M NaOH for
30 min and washed with TTBS before restaining. b-actin was used
to control for equal loading. For quantification, protein bands
were densitometrically measured using Quantity One software
(Bio-Rad).
Steroid Labeling
In whole-cell experiments, steroidogenesis was labeled by
adding 60,000 cpm [3H]DHEA per 12 well for 60 min. Steroids
were extracted from medium as described [29], and products were
separated by thin layer chromatography (TLC) (Macherey-Nagel,
Du¨ren, Germany) using the chloroform:ethylacetate (3:1) solvent
system. Radioactive steroids were visualized by exposing TLC
plates on imaging screens and reading them on a Fuji
PhosphoImager FLA-7000 (Fujifilm, Dielsdorf, Germany). Specif-
ic steroids were identified according to known standards and
densitometrically quantified using Multi Gauge software (Fujifilm).
Steroid conversion was calculated as percentage of total radioac-
tivity incorporated into specific products in relationship to total
amount of radioactivity added.
HSD3B2 Signaling Studies
NCI-R cells were cultivated in either growth or starvation
medium on 12-well plates for 24 hrs. Treatments were added to
fresh medium. Cells were treated with 0.5 mM 8Br-cAMP for 0 to
72 hours (short term –0 to 24 h; long term –24 to 72 h). The effect
of 8Br-cAMP on HSD3B2 was studied by promoter luciferase
assays, Western blots and steroid profiling as described above.
Further signaling studies involved the following inhibitors:
PD98059 MEK inhibitor (10 mM) [30], U0126 MEK inhibitor
(10 mM) [31] and H89 PKA inhibitor (10 mM) [32]. We treated
the NCI-R cells with PKA and MEK inhibitors in the presence
and absence of 8Br-cAMP under normal (GM) or starved (SM)
conditions for 48 hours before studying HSD3B2 expression and
activity by Western blot and steroid profiling.
Statistical Analysis
Statistical analysis was performed with the software Prism 4
(GraphPad Software, Inc. San Diego, CA) and Microsoft Windows
Excel 2003. Statistical differences between values were calculated
using the Student’s t test or the one-way ANOVA analysis.
Quantitative data represent the mean of at least three independent
experiments, error bars indicate the mean6SD. Significance was
set at *p,0.05, and **p,0.01.
Results
Transcriptional Regulation of HSD3B2
The HSD3B2 gene is specifically expressed in the adrenals and
the gonads. The promoter of HSD3B2 harbors binding sites for
the transcription factors GATA [21], the NGFIB family [22], the
liver receptor homolog (LRH1) [33], the steroidogenic factor 1
(SF1) [20] and the Stat family [25]. To study the transcriptional
Table 1. List of oligonucleotide primers used for cloning, site directed mutagenesis (SDM) and PCR.
Primers for HSD3B2 promoter constructs (M77144)
21050 HSD3B2 _F S: 59- CCGCTCGAGAGTGGGAACTCTGTGGGAATAA –39
2301 HSD3B2_F S: 59- CCGCTCGAGACTTGGAGACTTCTCCCAGTTT –39
2170 HSD3B2_F S: 59- CCGCTCGAGTTCTCTTCCTGTTCCTGG –39
2101 HSD3B2_F S: 59- CCGCTCGAGTTCTGGAGGAGGAGGGAGCAA –39
+53 HSD3B2_R AS: 59- GTCCCAAGCTTAGATTGTTAAAAGCTGGACAGAG –39
Primers for Nur77 cloning (BC016147)
Nur77 S: 59- CCCAAGCTTAGCCATGCCCTGTATCCAAGCC –39
AS: 59- CGCGGATCCTCAGAAGGGCAGCGTGTCC –39
Primers for SDM on HSD3B2 promoter constructs (M77144)
2301 HSD3B2/GATA mutation S: 59- CTAAAGCCAAGACTCTTTAAGACACTGTGGCCTT–39
2301 HSD3B2/NBRE mutation S: 59-GAATTAGAGATATAACCTAGAATTCACTATTATTCTGAGAAAAGG –39
2301 HSD3B2/SF1 mutation 59- GTATGTGGCAGGAGTTCAATTTAATAAGGGCTGAGAC–39
Primers for RT-PCR
Nur77 (NM_002135) S: 59- ATACACCCGTGACCTCAACC–39
AS: 59-CTTCTGGAAGCGGCAGAACT–39
HSD3B2 (NM_000198) S: 59- AAGCTGACTGTACTTGAAGG–39
AS: 59-GTGTACAAGGTATCACCATT–39
Restriction enzyme targeted sequences or consensus sequences are shown in bold. Mutated nucleotides are underlined. GenBank accession numbers for source
sequences are given in parentheses.
doi:10.1371/journal.pone.0068691.t001
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regulation of the human HSD3B2 gene, we prepared promoter
reporter constructs of different length (Figure 1A) and assessed
their activities in NCI-R cells upon transactivation with transcrip-
tion factors GATA4/6 and Nur77. We found that for HSD3B2
promoter activation the essential regulatory elements appear to lie
within the 2301 to +53 bp of the gene (Figure 1B). Both GATA4/
6 and Nur77 activated the 2301 bp and the 21050 bp constructs
similarly. Strongest activation was seen when GATA6 and Nur77
acted together on the HSD3B2 promoter constructs.
To further determine the role of GATA4/6, SF1 and Nur77
binding to the HSD3B2 promoter for its activity, we disrupted
their specific binding sites in the 2301 HSD3B2 promoter
luciferase reporter constructs. Wild-type and mutant promoter
reporters were then transfected into NCI-R cells and their
activation by transcription factors GATA4/6 and Nur77 was
assessed (Figure 2). Mutation of the GATA binding site in the
HSD3B2 promoter led to a specific loss of the GATA4/6 induced
promoter activation (Figure 2A). By contrast, mutation of the
NBRE/Nur77 binding site revealed not only a loss in Nur77
transactivation but also caused a loss in GATA4/6 promoter
transactivation suggesting an important collaboration between
these two factors (Figure 2B). Conversely, mutation of the SF1
binding site rather increased transcriptional activation by
GATA4/6, especially when combined with Nur77 (Figure 2C).
GATA, SF1 and Nur77 are Essential for Tissue Specific
HSD3B2 Expression
Human HSD3B2 is expressed in the adrenal cortex and in the
gonads but not in the placenta which expresses HSD3B1 for
progesterone biosynthesis from pregnenolone [34,35]. Although
HSD3B1 and B2 are approximately 89% identical at the level of
the DNA coding sequence and 93.5% identical at the protein level
[2], the 21050 bp HSD3B2 promoter sequence differs signifi-
cantly from the type 1 promoter. JEG3 cells do not express
HSD3B2 and have a weak or no expression of the transcription
factors GATA4/6, SF1 and Nur77 [27,36]. We therefore
hypothesized that those transcription factors might be essential
for HSD3B2 expression. To address this question, we transfected
JEG3 cells and non-steroidgenic HEK293 cells with the21050 bp
HSD3B2 promoter reporter construct and the candidate tran-
scription factors (Figure 3). As predicted, the HSD3B2 promoter
construct was inactive in both JEG3 and HEK293 cells (Figure 3A).
Co-transfection with GATA4/6, SF1 or Nur77 alone was not able
to activate the promoter construct. We observed a very significant
activation of the HSD3B2 promoter only when all three
transcription factors were combined. The control experiment in
non-steroidogenic HEK293 cells revealed similar results
(Figure 3B). Thus, we concluded that the transcription factors
GATA4/6, SF1 and Nur77 work in concert to regulate HSD3B2
gene expression.
Figure 1. Essential transcription regulatory elements of the HSD3B2 promoter. (A) Diagram of the HSD3B2 promoter up to 21050 bp
upstream with localization of identified transcription factor binding sites. (B) Activity of different HSD3B2 promoter reporter constructs when
stimulated with different transcription factors. NCI-R cells were transiently transfected with HSD3B2 promoter luciferase reporter vectors and
transcription factors GATA4/6 and Nur77 as indicated. Promoter activation was assessed by the dual luciferase assay (Promega) using pRL-TK as
internal control. Essential activation of the HSD3B2 promoter by these factors seems to lie within the 2301 HSD3B2 construct. Both GATA and Nur77
activate the promoter with strongest activation seen by GATA6/Nur77 in combination. Data are expressed as fold over vector control and given as
mean6SD of three independent experiments performed in duplicate. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0068691.g001
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With these results, we wondered whether GATA4/6, SF1 and
Nur77 would be also sufficient to activate the endogenous
HSD3B2 gene in JEG3 or HEK293 cells. Therefore, we
transfected these cells with GATA4/6, SF1 or Nur77 either alone
or in combination and assessed endogenous HSD3B2 expression
either by RT-PCR on total extracted RNA or by Western blot
from protein extracts. While RT-PCR revealed inconsistent
results, Western blots were clearly negative for endogenous
HSD3B2 expression after transfection of JEG3 or HEK293 cells
with GATA4/6, SF1 and Nur77 (data not shown).
Since some genes involved in steroidogenesis are regulated by
epigenetic modifications [37,38,39], HSD3B2 was investigated for
Figure 2. Role of transcription binding elements GATA, NBRE/Nur77 and SF1 for the activation of the HSD3B2 promoter in NCI-R
cells. (A–C) Promoter activation by GATA and Nur77 was studied in NCI-R cells transiently transfected with 2301 bp HSD3B2 promoter luciferase
reporter constructs harboring specific binding site mutations. (A) Mutation of the GATA binding site in the 2301 HSD3B2 construct showing loss of
GATA induced promoter activation. (B) Mutation of the NBRE/Nur77 binding site revealing not only loss in Nur77 but also GATA4/6 induced promoter
activation. (C) Mutation of the SF1/LRH binding site showing rather an increase in HSD3B2 promoter activation. Data are expressed as fold over vector
control and given as mean6SD of three independent experiments. * p,0.05, ** p,0.01, (a) p = 0.26, (b) p = 0.060.
doi:10.1371/journal.pone.0068691.g002
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possible methylation and/or acetylation. JEG3 cells were treated
with the histone methyltransferase inhibitor 5-aza-dC and/or the
histone deacetylase inhibitor TSA and thereafter HSD3B2 as well
as CYP17A1 expression (control) was assessed by quantitative RT-
PCR as described [27,40]. Neither 5-aza-dC nor TSA treatment
was found to induce HSD3B2 expression in JEG3 cells (data not
shown), while CYP17A1 expression was clearly inducible as
previously reported [27]. These results indicate that the HSD3B2
gene is not regulated epigenetically.
Effect of Serum Starvation on HSD3B2 in NCI-R Cells
The human adrenocortical NCI-R cell line is widely used for
studies of steroidogenesis. NCI-R cells express HSD3B2 and
produce all three types of adrenal steroid hormones, e.g.
mineralocorticoids, glucocorticoids, and androgens [41]. NCI-R
cells are usually cultured in growth medium containing 5% serum
and insulin (www.atcc.org), but we and others observed that they
can easily survive in serum free medium, and without insulin for at
least 4 days [42,43]. However, in our previous studies we have also
observed that starvation conditions changed the steroid profile of
NCI-R cells [44]. Therefore we aimed to investigate the
differential regulation of HSD3B2 in NCI-R cells under normal
growth and starvation conditions (Figure 4).
To test the impact of different growth conditions on HSD3B2
promoter activity, we transfected NCI-R cells with the 21050bp
HSD3B2 promoter and grew the cells for up to 96 hours under
normal growth or starvation conditions (Figure 4A). Compared to
normal growth medium, starvation conditions caused a 60% loss
of HSD3B2 promoter activity in NCI-R cells within the first 24 h.
Overall, HSD3B2 promoter activity decreased under both normal
growth and starvation conditions over time, but a more important
decrease was observed for cells cultivated in normal growth
medium over 96 h when they reached a promoter activity level
similar to starvation conditions after 24 h (Figure 4A). At the
protein level, we observed a significant decrease in HSD3B2
expression over 72 hrs under starvation conditions (Figure 4B). In
addition, HSD3B2 expression was significantly lower under
starvation (SM) than normal growth (GM) conditions (Figure 4B),
a finding which fitted with the observed results for HSD3B2
promoter studies (Figure 4A). Finally, HSD3B2 activity was
assessed in NCI-R cells grown for 96 h in both conditions.
Conversion of labeled DHEA to androstenedione was compared
(Figure 4C). Only under starvation conditions was a decrease in
the conversion of DHEA to androstenedione and thus HSD3B2
activity observed. This decrease was significant after 72 h (230%).
In summary, all these experiments clearly showed that starvation
led to an inhibition of HSD3B2.
Bearing in mind that timed HSD3B2 expression during fetal life
is regulated by timed Nur77 expression [9], we also assessed
Nur77 expression of NCI-R cells grown under starvation
conditions. However, while starvation clearly decreased HSD3B2
expression after 24 hours, no such change was observed for Nur77
(data not shown).
Regulation of HSD3B2 by cAMP
Adrenocorticotropic hormone (ACTH) is the most important
regulator of adrenal glucocorticoid biosynthesis and a co-regulator
of adrenal androgen production [45,46,47]. ACTH acts via its G-
protein coupled receptor which predominantly activates the
second messenger cAMP, and that in turn leads to the activation
of the cAMP-dependent kinase (PKA) [45]. It is well recognized
that stimulation of the ACTH/cAMP signaling pathway may have
acute (short term) as well as chronic (long term) effects on
steroidogenesis [47,48,49]. We investigated both the short and the
long term effect of 8Br-cAMP stimulation on HSD3B2 in NCI-R
cells.
Short term effects: We studied the activity of the 2301 bp
HSD3B2 promoter construct in NCI-R cells cultured in normal
growth or starvation medium with or without 8Br-cAMP
stimulation for 24 h (Figure 5A). By mutating the GATA,
NBRE/Nur77 or SF1 binding sites in the promoter constructs,
we assessed which transcription factor might be involved in the
cAMP targeted regulation. Eight Br-cAMP stimulation increased
HSD3B2 promoter activity in either growth medium. Mutating
the GATA binding site in the reporter construct did not abolish
cAMP stimulation. By contrast, mutations of the NBRE/Nur77
and SF1 binding sites diminished basal promoter activity but only
mutated NBRE/Nur77 diminished or abolished the cAMP effect
(Figure 5A). Therefore, it appears that cAMP stimulation of the
HSD3B2 promoter depends on an intact NBRE/Nur77 binding
site.
Figure 3. Identification of essential transcription factors for
human HSD3B2 expression. Both steroidogenic human placental
JEG3 and non-steroidgenic human embryonic kidney HEK293 cells
(which do not express HSD3B2 normally) were transfected with the
human 21050 HSD3B2 promoter construct and stimulated with
different transcription factors. Promoter activation was assessed by
the dual luciferase assay (Promega) using pRL-TK as internal control. (A)
In JEG3 cells only transcription factors GATA, SF1 and Nur77 together
are able to activate the HSD3B2 promoter. (B) Similar results are
observed in non-steroidgenic HEK293 cells. Data are expressed in
Relative Light Units (RLU). Error bars show the mean6SD of three
independent experiments. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0068691.g003
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Furthermore, we determined short term effects of 8Br-cAMP on
protein expression and enzyme activity of HSD3B2 in NCI-R cells
(Figure 5B–C). Cells were grown in different growth medium and
stimulated with 8Br-cAMP for 0 to 24 h. Western blot analysis
revealed no significant change in HSD3B2 protein expression after
cAMP stimulation in both growth conditions (Figure 5B).
HSD3B2 enzyme activity was assessed from the conversion of
DHEA to androstenedione, and was found to decrease over time
under both growth conditions (Figure 5C). Overall, after short
term 8Br-cAMP stimulation, HSD3B2 DHEA to androstenedione
conversion rate was lower in starvation medium than growth
medium (SM 43% versus GM 51% after 24 h), and was lower
after 8Br-cAMP stimulation and cell growth for 24 hours
(Figure 5C) than after 24 h cell growth in either medium alone
(Figure 4C) suggesting an additive short term inhibitory effect of
starvation and 8Br-cAMP.
Long term effects of cAMP: Similar to short term, the effect of
long term (24–72 hours) 8Br-cAMP stimulation on protein
expression and enzyme activity of HSD3B2 was studied in NCI-
R cells under both growth and starvation conditions. We observed
an increase in HSD3B2 expression after 24 h of 8Br-cAMP
stimulation which was clearly significant after 72 h under both
growth conditions (Figure 6A). HSD3B2 activity studies assessing
conversion of DHEA to androstenedione revealed that without
8Br-cAMP (basal conditions) HSD3B2 activity significantly
decreased over the first 48 h under both growth conditions and
tended to increase thereafter. By contrast, 8Br-cAMP stimulation
decreased HSD3B2 activity after 24 hours but led to no further
loss of activity after 36 or 48 h for growth versus starvation
Figure 4. HSD3B2 expression and activity in NCI-R cells under normal and starvation growth conditions. (A) HSD3B2 promoter activity
was assessed in NCI-R cells grown in normal growth medium (GM) and in medium without serum and ITS (starvation medium; SM) for 96 h. NCI-R
cells were transiently transfected with empty vector and the 21050 HSD3B2 promoter luciferase construct. Promoter activation was assessed by the
dual luciferase assay (Promega) using pRL-TK as internal control. Data are expressed as fold over vector control and error bars show the mean6SD of
three independent experiments. (B) HSD3B2 expression under different growth conditions was assessed by Western blot analysis. Cells were grown
for 24, 48, 72 hours in normal medium (GM) and in starvation medium (SM). b-actin served as loading control. Representative Western blots are
shown. Quantitative results of three independent experiments are also depicted giving the mean6SD. (C) Activity of HSD3B2 for converting DHEA to
androstenedione under either GM or SM growth conditions. NCI-R cells were grown for 96 h. Steroid production was labeled with [3H]DHEA for
60 min. Steroids were extracted and resolved by TLC. HSD3B2 activity was assessed by calculating the conversion of [3H]DHEA to
[3H]androstenedione (%). A representative steroid profile (TLC) is shown (left) and the quantification of four independent experiments (mean6SD)
is given (right). *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0068691.g004
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Figure 5. Regulation of HSD3B2 by 8Br-cAMP – short term. (A) NCI-R cells were transfected with the2301 HSD3B2 constructs with or without
mutated GATA or NBRE/Nur77 transcription binding sites before stimulation with 0.5 mM 8Br-cAMP for 24 h under GM and SM growth conditions.
Cyclic AMP stimulation of the HSD3B2 promoter seems to depend on an intact NBRE/Nur77 binding site. Data are expressed as fold over vector
control (%) and error bars show the mean6SD of three independent experiments. (B) Effect of 8Br-cAMP stimulation on HSD3B2 expression was also
assessed in NCI-R cells grown either under normal (GM) or starved (SM) conditions for 0–24 h. Expression was assessed by Western blot analysis using
Regulation of HSD3B2 in NCI-H295R Cells
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conditions respectively (Figure 6B). Taken together long term
(chronic) cAMP stimulation seems to increase HSD3B2 expression
and support its activity.
Role of PKA Signaling for HSD3B2 Regulation
It is well described that the ACTH/ACTH receptor complex
activates the cAMP/PKA and the MEK/ERK1/2 signaling
pathways in adrenal cells [45,50] Therefore, after showing that
HSD3B2 is clearly regulated by 8Br-cAMP (Figures 5, 6), we
studied these signaling pathways in more detail. To determine the
role of PKA on HSD3B2 regulation, we treated NCI-R cells with
the PKA inhibitor H89 in the presence and absence of 8Br-cAMP
under normal (GM) or starved (SM) conditions for 48 h. Western
blot showed that under 8Br-cAMP stimulation HSD3B2 expres-
sion increased under both growth conditions (Figure 7A). By
contrast, PKA inhibitor treatment significantly decreased the
expression of HSD3B2 suggesting a role for PKA for HSD3B2
expression. However, the PKA inhibitor was not able to block
cAMP stimulation on HSD3B2 indicating that the cAMP effect is
not mediated through PKA signaling (Figure 7A). At the level of
HSD3B2 activity, we found that 8Br-cAMP stimulation and H89
PKA inhibitor treatment caused a marked decrease in the
conversion of DHEA to androstenedione under both cell growth
conditions, but their effect was not additive (Figure 7B).
Role of MAPK/ERK Signaling for HSD3B2 Regulation
Similar to PKA, we studied the effect of MAPK/ERK signaling
on HSD3B2. NCI-R cells were treated with the MAPK/ERK
inhibitors PD98059 and U0126 in presence and absence of 8Br-
cAMP stimulation under normal (GM) or starved (SM) conditions
for 48 h. PD98059 inhibits MEK1 [30] while U0126 inhibits both
MEK1 and MEK2 kinases [31]. We observed that PD98059
inhibitor did not affect HSD3B2 expression under both growth
conditions (Figure 8A). By contrast, U0126 inhibitor significantly
decreased HSD3B2 expression especially under normal growth
conditions. But cAMP stimulation was still effective under U0126
inhibitor treatment suggesting that cAMP does not employ
MAPK/ERK signaling for its effect. Overall, effects were
significant only under normal growth conditions but showed a
similar pattern under starvation conditions (Figure 8A). HSD3B2
activity studies revealed no effect for PD98059 inhibitor treatment
with and without 8Br-cAMP stimulation. But a significant
decrease for DHEA to androstenedione conversion was found
for U0126 inhibitor treatment under 8Br-cAMP stimulation
(Figure 8B). This suggests an additive effect and precludes that
the effect of cAMP is mediated through MAPK/ERK signaling.
Discussion
In this study, we elucidated mechanisms regulating HSD3B2 for
steroid hormone biosynthesis in human adrenal NCI-H295R cells.
So far, it has been shown that the steroidogenic enzyme HSD3B2
which is essential for the production of all steroid hormones, is
regulated at the transcriptional level by specific transcription
factors [20,21,22,25] and through hormonal stimulation such as
ACTH and follicle stimulating hormone (FSH) [23,51]. Previous
studies reported that for transcriptional regulation of HSD3B2,
GATA factors synergize with SF1 to activate the HSD3B2
promoter and stimulate steroidogenesis [21,52]. Similarly, it has
been shown that Nur77 and SF1/LRH1 co-activate the human
HSD3B2 promoter and that all these transcription factors have
their specific binding sites in the HSD3B2 promoter [22]. We now
showed that all these factors work in concert to activate the
promoter of the HSD3B2 gene. Accordingly, reporter constructs
containing the regulatory elements of all these transcription factors
are most active and combined overexpression of GATA together
with Nur77 transcription factors enhance promoter activity most.
Conversely, disrupting promoter binding sites of GATA and
NBRE inhibits HSD3B2 promoter activity, and this is not only
true for Nur77 stimulation but also for GATA stimulation when
disrupting the NBRE site thereby suggesting a relevant collabo-
ration between the transcription factors GATA and Nur77. By
contrast, no such negative effect could be observed when
destroying the SF1/LRH1 site at 264 bp in the promoter
indicating that SF1/LRH1 regulate HSD3B2 indirectly through
other regulatory complexes including GATA and Nur77. Overall
our studies suggest that Nur77 predominantly is an essential
transcriptional factor for HSD3B2 expression. In line with this,
other investigators have also reported that the cis-element NBRE
at 2130 bp is both necessary and sufficient for Nur77 to activate
the human HSD3B2 promoter in steroidogenic adrenal cells [22].
Therefore, we tested whether human HSD3B2 which is normally
not expressed in placental JEG3 cells, might be transactivated
through overexpression of Nur77 in JEG3 cells that have a weak
or no expression of Nur77, SF1 and GATA4/6 [27,36]. However,
we found that Nur77 alone was not able to stimulate the HSD3B2
promoter, neither in JEG3 nor in non-steroidogenic HEK293
cells. Only overexpression of Nur77 with GATA and SF1 together
seemed to stimulate the HSD3B2 promoter luciferase reporter. By
contrast, overexpression of all these transcription factors failed in
activating endogenous HSD3B2 expression. However, this nega-
tive result might be explained by too low transfection efficiency, so
that expression levels of GATA/Nur77/SF1 in transfected cells
were insufficient for activating endogenous HSD3B2. Expression
levels of transcription factors are usually sufficient to induce effects
when using reporter genes such as luciferase because this is a more
sensitive endpoint. Alternatively, yet undiscovered gene expression
control mechanisms may play a role.
Thus, we thought of additional epigenetic control of HSD3B2
expression as previously seen for the CYP17A1 gene which is
similarly important for steroidogenesis in general and androgen
production in particular (27). But our epigenetic studies revealed
that neither acetylation nor methylation control the expression of
the HSD3B2 gene in JEG3 cells.
Serum free starvation growth conditions have been shown to
alter the steroid profile of NCI-R cells significantly by markedly
increasing androgen production [44]. Therefore, we have been
using the starved NCI-R cell model successfully for our studies of
androgen regulation [40,44,53] or for studying mechanisms of
action of androgen lowering drugs such as metformin [53]. Under
starvation conditions a shift in the steroid profile of NCI-R cells
towards DHEA and androstenedione synthesis was noted due to
an increase of CYP17A1-17,20 lyase activity and a dramatic
decrease of HSD3B2 activity [44]. As the physiologic event of
adrenarche is also characterized by a decrease in HSD3B2 activity
in the zona reticularis of the adrenal cortex [13], we remain
specific antibodies. b-actin served as loading control. Representative Western blots are shown. Quantitative results summarize three independent
experiments (mean6SD). (C) HSD3B2 activity under 8Br-cAMP stimulation for up to 24 h. NCI-R cells were grown and treated with 0.5 mm 8Br-cAMP
for 0–24 h under GM and SM growth conditions. The HSD3B2 activity for converting [3H]DHEA to [3H]androstenedione (%) was assessed. Steroids
were extracted and resolved by TLC as depicted. Quantification of three independent experiments (mean6SD) is shown. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0068691.g005
Regulation of HSD3B2 in NCI-H295R Cells
PLOS ONE | www.plosone.org 9 July 2013 | Volume 8 | Issue 7 | e68691
Figure 6. Regulation of HSD3B2 expression and activity by 8Br-cAMP – long term. (A) Effect of 8Br-cAMP stimulation on HSD3B2
expression was assessed in NCI-R cells grown either under normal (GM) or starved (SM) conditions for 24, 36, 48 and 72 hours. Expression was
assessed by Western blot analysis using specific antibodies. b-actin served as loading control. Representative Western blots are shown. Quantitative
results summarize three independent experiments (mean6SD). (B) HSD3B2 activity under 8Br-cAMP stimulation for up to 72 h. NCI-R cells were
grown and treated with 0.5 mm 8Br-cAMP for 24, 36, 48 and 72 hours. HSD3B2 activity for converting [3H]DHEA to [3H]androstenedione (%) was
assessed. Steroids were extracted and resolved by TLC as depicted. Quantification of three independent experiments (mean6SD) is shown. * p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0068691.g006
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interested in the regulatory events underlying HSD3B2 inhibition
following starvation. Our new experiments revealed that this
inhibition of HSD3B2 involves gene transcription, protein
expression and function. Although it has been shown that specific
expression of transcription factor Nur77 plays a crucial role for
HSD3B2 expression during fetal adrenal development [9] and for
adrenal zonation [24], starvation does not alter Nur77 expression
Figure 7. Role of PKA signaling for HSD3B2 expression and activity. (A) Effect of PKA inhibitor on HSD3B2 expression in presence and
absence of 8Br-cAMP stimulation was assessed in NCI-R cells grown either under normal (GM) or starved (SM) conditions for 48 h. Expression was
assessed by Western blot analysis using specific antibodies. b-actin served as loading control. Representative Western blots are shown. Quantitative
results summarize three independent experiments (mean6SD). (B) HSD3B2 activity under PKA inhibition in presence and absence of 8Br-cAMP
stimulation in NCI-R cells grown either in normal (GM) or starved (SM) conditions for 48 h. HSD3B2 activity for converting [3H]DHEA to
[3H]androstenedione (%) was assessed. Steroids were extracted and resolved by TLC as depicted. Quantification of three independent experiments
(mean6SD) is shown. * p,0.05.
doi:10.1371/journal.pone.0068691.g007
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in NCI-R cells. Most likely, Nur77 is therefore not the regulator of
the starvation effect on HSD3B2.
ACTH is the key hormone regulating glucocorticoid and
androgen biosynthesis of the adrenal cortex [1]; it also acts as a
developmental and growth factor for the adrenals [54]. ACTH
exerts its effect via a G-protein coupled receptor (melanocortin 2
receptor) which predominantly activates the second messenger
cAMP, and that in turn leads to the activation of kinases which
phosphorylate transcription factors regulating steroidogenesis
[45,47]. Cyclic AMP regulation of steroidogenesis appears to
Figure 8. Role of MAPK/ERK1/2 signaling for HSD3B2 expression and activity. (A) Effect of MEK inhibitors on HSD3B2 expression in
presence and absence of 8Br-cAMP stimulation assessed in NCI-R cells grown in normal (GM) or starvation (SM) medium for 48 h. Expression was
assessed by Western blot analysis using specific antibodies. b-actin served as loading control. Representative Western blots are shown. Quantitative
results summarize three independent experiments (mean6SD). (B) HSD3B2 activity under MEK inhibition in presence and absence 8Br-cAMP
stimulation assessed in NCI-R cells grown either in normal (GM) or starved (SM) conditions for 48 h. The HSD3B2 activity for converting [3H]DHEA to
[3H]androstenedione (%) was assessed. Steroids were extracted and resolved by TLC as depicted. Quantification of three independent experiments
(mean6SD) is shown. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0068691.g008
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target many genes including steroidogenic acute regulatory protein
StAR and CYP17A1 [47,55,56]. So far, little is known on the
effect of cAMP on HSD3B2. We demonstrated that cAMP
stimulates the HSD3B2 promoter. It appears that the cAMP
dependent signaling targets the HSD3B2 promoter through the
NBRE/Nur77 binding site. Previous studies on regulation of
steroidogenesis have also suggested that Nur77 is most sensitive to
hormonal regulation (e.g. luteinizing hormone (LH), ACTH and
angiotensin II), although SF1 and LRH1 expression were also
slightly affected [57,58,59,60].
Generally, ACTH/cAMP stimulation may act on steroid
hormone biosynthesis acutely (short term) or chronically (long
term). Both the acute and chronic ACTH responses seem to be
transmitted via cAMP-dependent signaling pathways and they
occur in the order of minutes to hours [47]. Our study revealed
that in response to short term cAMP stimulation HSD3B2 protein
expression remained unaltered but HSD3B2 activity was inhibited
indicating that there is an acute cAMP effect that bypasses gene
transcription and protein expression. However, the exact (signal-
ing) mechanism underlying this effect remains elusive. Possible
mechanisms for direct HSD3B2 enzyme regulation which could
be considered include the following: First, posttranslational
modification of the HSD3B2 protein such as phosphorylation,
glycosylation, ubiquitination and proteolysis changing enzyme
amount or enzyme characteristics (substrate/co-factor specificity);
second, cAMP might have a direct or indirect effect on co-factor
and/or substrate availability for the enzyme. Finally, recently it
has been shown that mitochondrial membrane translocases which
associate with HSD3B2 are able to modulate enzyme activity
through protein conformation change [61]. Most of these possible
mechanisms need to be investigated for cAMP regulating
HSD3B2 in future studies. Some experiments regarding protein
degradation modulating basal and cAMP stimulated HSD3B2
expression using the proteasome inhibitor MG132 have been
performed in our laboratory but revealed no change on protein
expression (unpublished data).
By contrast, long term cAMP stimulation increases HSD3B2
expression after 24 hours resulting in a halt of HSD3B2 inhibition
after 48 hours. Thus the long term effect of cAMP treatment is
clearly at the level of HSD3B2 transcription and expression. In
line with that, previous reports also show that cAMP stimulation
modulates HSD3B2 expression through transcriptional regulation
[62,63].
ACTH/cAMP signaling in steroidogenesis is extremely complex
and not fully understood [47]. Nevertheless a cross-talk between
cAMP/PKA and other signaling pathways such as MEK/ERK1/
2 or phosphatidyl-inositol 3-kinase/protein kinase B has been
established by several studies [63,64]. In mouse Leydig cells, LH
and 8Br-cAMP have been shown to stimulate phosphorylation of
ERK by PKA-dependent activation of Ras [65]. In our study we
investigated cAMP regulated pathways PKA and MEK/ERK1/2
to determine their possible role in HSD3B2 regulation under
different growth conditions. While inhibition of PKA is seen to
inhibit HSD3B2 expression, it does not prevent cAMP from
stimulating HSD3B2 indicating that cAMP does not (only) signal
through this pathway. Similarly, inhibition of MEK1/2 results in a
significant decrease of HSD3B2 expression without inhibiting the
cAMP effect therefore suggesting that the MAPK pathway is also
not crucial for cAMP signaling. Overall, both PKA and MAPK
signaling pathways appear to modulate HSD3B2, however the
main downstream signaling of cAMP to target HSD3B2 remains
elusive. Moreover, observed effects of our signaling studies were
similar under both normal and starvation growth conditions
indicating that cAMP regulation as well as PKA and MEK/ERK
pathways are not key modulators of the starvation cell program.
Therefore, other regulators must be considered in future studies.
Possible candidates include Src kinase (SRC), protein kinase C
(PKC), and calcium-dependent calmodulin kinases (CaMK) which
have been shown to mediate angiotensin II stimulation on
HSD3B2 expression for aldosterone production through induction
of rapid response genes (e.g. members of the NGFI-B family) as
well as through phosphorylation of transcription factors and the
cAMP-response element binding protein (CREB) [66].
In summary, through our studies we gained further insight into
the regulation of HSD3B2 which plays a key role in steroidogen-
esis in health and disease. We confirm that HSD3B2 is specifically
regulated at the transcriptional level with transcription factor
Nur77 being essential but not sufficient for HSD3B2 expression.
Importantly, short term cAMP stimulation seems to inhibit
HSD3B2 activity directly while under long term cAMP stimula-
tion HSD3B2 transcription and expression are increasing.
Downstream signaling of cAMP does not depend on PKA or
MEK/MAPK/ERK signaling although these pathways modulate
HSD3B2 expression under basal conditions. Starvation inhibits
HSD3B2 expression significantly by cellular mechanisms yet to be
illustrated.
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